EphB4 Cellular Kinase Activity Assayed Using an Enzymatic Protein Interaction System

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Assay and drug development technologies

• Publication date

  2013-05-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1089/adt.2012.490PMID 23557019
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibitors of the Tyrosine Kinase EphB4. Part 3. Identification of Non-benzodioxole-Based Kinase Inhibitors.

  2011cited by this paper
• Therapeutic interference with EphrinB2 signalling inhibits oxygen‐induced angioproliferative retinopathy

  2011cited by this paper
• Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series.

  2011cited by this paper
• Ephrin B2/EphB4 pathway in hepatic stellate cells stimulates Erk-dependent VEGF production and sinusoidal endothelial cell recruitment.

  2010cited by this paper
• Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors.

  2010cited by this paper
• Imidazo[1,2-a]pyrazine Diaryl Ureas: Inhibitors of the Receptor Tyrosine Kinase EphB4.

  2010cited by this paper
• Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth.

  2010cited by this paper
• Eph and ephrin interactions in bone.

  2010cited by this paper
• Converging Evidence for Efficacy from Parallel EphB4-Targeted Approaches in Ovarian Carcinoma

  2010cited by this paper
• Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro.

  2010cited by this paper
• Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4.

  2009cited by this paper
• Soluble ephrin-B2 mediates apoptosis in retinal neovascularization and in endothelial cells.

  2009cited by this paper
• The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.

  2009cited by this paper
• Humanized anti-EphB4 antibodies for the treatment of carcinomas and vasculogenesis-related diseases

  2009cited by this paper
• Development of a Cell-Based Assay for Measurement of c-Met Phosphorylation Using AlphaScreenTM Technology and High-Content Imaging Analysis

  2009cited by this paper
• Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers

  2008cited by this paper
• Structure‐based tailoring of compound libraries for high‐throughput screening: Discovery of novel EphB4 kinase inhibitors

  2008cited by this paper
• Brothers and sisters: molecular insights into arterial-venous heterogeneity.

  2008cited by this paper
• Crystal Structure and NMR Binding Reveal That Two Small Molecule Antagonists Target the High Affinity Ephrin-binding Channel of the EphA4 Receptor*

  2008cited by this paper
• Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines.

  2008cited by this paper
• Label-free cell-based functional assays.

  2008cited by this paper
• Inhibitors of the tyrosine kinase EphB4. Part 2: structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines.

  2008cited by this paper
• High-content analysis of kinase activity in cells.

  2008cited by this paper
• Paradoxes of the EphB4 receptor in cancer.

  2007cited by this paper
• β Galactosidase Complementation: A Cell-Based Luminescent Assay Platform for Drug Discovery

  2007cited by this paper
• EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival

  2006cited by this paper
• The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl–Crk pathway

  2006cited by this paper
• Luminescent imaging of β-galactosidase activity in living subjects using sequential reporter-enzyme luminescence

  2006cited by this paper
• The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth.

  2006cited by this paper
• Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.

  2006cited by this paper
• EPHB4 and survival of colorectal cancer patients.

  2006cited by this paper
• Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma

  2005cited by this paper
• EphB4 expression and biological significance in prostate cancer.

  2005cited by this paper
• Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy.

  2005cited by this paper
• Enzymatic detection of protein translocation

  2005influential reference
• Pneumomediastinum and abdominal pain: which correlation?

  2005cited by this paper
• EphB Receptor-binding Peptides Identified by Phage Display Enable Design of an Antagonist with Ephrin-like Affinity*

  2005cited by this paper
• Inhibition of tumor growth and angiogenesis by soluble EphB4.

  2004cited by this paper
• EphB4 signaling is capable of mediating ephrinB2-induced inhibition of cell migration.

  2004cited by this paper
• Eph B4 Receptor Signaling Mediates Endothelial Cell Migration and Proliferation via the Phosphatidylinositol 3-Kinase Pathway*

  2002cited by this paper
• Enzyme Fragment Complementation: A Flexible High Throughput Screening Assay Technology

  2002cited by this paper
• The ephrins and Eph receptors in angiogenesis.

  2002cited by this paper
• The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration.

  2001cited by this paper
• Eph receptors and ephrin ligands. essential mediators of vascular development.

  2000cited by this paper
• Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development.

  1999cited by this paper
• Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4.

  1998cited by this paper
• By–Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling

  1992cited by this paper
• Making antibody fragments using phage display libraries

  1991cited by this paper

• Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models

  2016cites this paper